CIS Bio to license tracer technology

Article

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new technetium-labeled compounds. The agreementincludes rights for a nuclear cardiology agent that shows promisein imaging myocardial ischemia and infarction, according to thecompany.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.